Table of Contents
<< Previous Issue | May 2015 (Vol: 2015, Issue: 5) | Next Issue >> |
- Section: Licensing
-
AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma
-
Bayer Augments Thrombosis Pipeline by Licensing ISIS-FXIRx from Isis Pharmaceuticals
- Section: Mergers & Acquisitions
-
Teva Returns to M&A with US$3.5 B Auspex Pharma Purchase Before Making US$40 B Approach for Mylan
-
Alexion to Acquire Synageva for US$8.4 B to Diversify its Rare Disease Portfolio